Aligos Therapeutics announced positive topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta agonist, in metabolic-dysfunction associated steatohepatitis subjects. Doses of 0.5 mg to 0.9 mg ALG-055009 demonstrated statistically significant reductions in liver fat at Week 12, with placebo-adjusted median relative reductions up to 46.2% as measured by MRI-PDFF. Up to 70% of subjects achieved greater than or equal to30% relative reduction in liver fat compared to baseline. ALG-055009 demonstrated a favorable tolerability profile with no serious adverse events, or clinical hyper/hypothyroidism.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGS:
- Closing Bell Movers: Steelcase down 10% on soft top-line results, guidance
- Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
- Aligos Therapeutics to announce Phase 2a topline results for ALG-055009 in MASH
- Aligos Therapeutics announces inducement grants under Nasdaq listing rule
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)